title: Antimetastatic activity of a novel mechanism-based gelatinase inhibitor.
abstract: Matrix metalloproteinases (MMPs), and in particular gelatinases (MMP-2 and MMP-9), play a key role in cancer progression. However, clinical trials in which MMP inhibitors were tested in cancer patients have been disappointing. Whereas many reasons have been postulated to explain the failure of the clinical trials, lack of inhibitor selectivity was a major limitation. Thus, despite the consensus opinion that MMP-mediated proteolysis is essential for cancer progression and that certain MMPs represent important targets for intervention, effective and selective inhibition of those MMPs remains a major challenge in drug development. We previously reported the first mechanism-based MMP inhibitor, designated SB-3CT, which is a selective gelatinase inhibitor. Here we report that SB-3CT (5-50 mg/kg/d) is a potent inhibitor of liver metastasis and increases survival in an aggressive mouse model of T-cell lymphoma. This study shows that mechanism-based inhibition of gelatinases represents a novel approach to inhibitor design that promises to be a successful anticancer therapy.
authors.affiliation: Institut für Experimentelle Onkologie und Therapieforschung der Technischen Universität München, Munich, Germany.
authors.forename: Achim
authors.initials: A
authors.lastname: Krüger
authors.forename: Matthias J E
authors.initials: MJ
authors.lastname: Arlt
authors.forename: Michael
authors.initials: M
authors.lastname: Gerg
authors.forename: Charlotte
authors.initials: C
authors.lastname: Kopitz
authors.forename: M Margarida
authors.initials: MM
authors.lastname: Bernardo
authors.forename: Mayland
authors.initials: M
authors.lastname: Chang
authors.forename: Shahriar
authors.initials: S
authors.lastname: Mobashery
authors.forename: Rafael
authors.initials: R
authors.lastname: Fridman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D006573:Heterocyclic Compounds, 1-Ring / Q000494:pharmacology*; D008114:Liver Neoplasms, Experimental / Q000201:enzymology / Q000517:prevention & control* / Q000556:secondary*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000201:enzymology / Q000517:prevention & control; D061965:Matrix Metalloproteinase Inhibitors; D051379:Mice; D008811:Mice, Inbred DBA; D011480:Protease Inhibitors / Q000494:pharmacology*; D013450:Sulfones / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D006573:Heterocyclic Compounds, 1-Ring; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; C429533:SB 3CT compound; D013450:Sulfones